RT Journal Article
T1 Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
A1 Jiménez-Ubieto, Ana
A1 Grande, Carlos
A1 Caballero, Dolores
A1 Yáñez, Lucrecia
A1 Novelli, Silvana
A1 Hernández-Garcia, Miguel Teodoro
A1 Manzanares, María
A1 Arranz, Reyes
A1 Ferreiro, José Javier
A1 Bobillo, Sabella
A1 Mercadal, Santiago
A1 Galeo, Andrea
A1 López Jiménez, Javier
A1 Moraleda, José María
A1 Vallejo, Carlos
A1 Albo, Carmen
A1 Pérez, Elena
A1 Marrero, Carmen
A1 Magnano, Laura
A1 Palomera, Luis
A1 Jarque, Isidro
A1 Martínez-Sánchez, Pilar
A1 Martín, Alejandro
A1 Coria, Erika
A1 López-Guillermo, Armando
A1 Salar, Antonio
A1 Lahuerta, Juan José
K1 Autologous stem cell
K1 Follicular lymphoma
K1 Long-term follow-up
K1 Rituximab
K1 Trasplantation
AB High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free chemotherapy regimen. A total of 655 patients with FL were reported to the Spanish GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) registry and underwent first ASCT between 1989 and 2007. A total of 203 patients underwent ASCT in first complete response (CR1), 174 in second complete response (CR2), 28 in third complete response (CR3), 140 in first partial response (PR1), 81 in subsequent PR, and 29 with resistant/refractory disease; 184 patients received rituximab before ASCT. With a median follow-up of 12 years from ASCT, median progression-free survival (PFS) and overall survival (OS) were 9.7 and 21.3 years, respectively. Actuarial 12-year PFS and OS were 63% (95% confidence interval [CI], 58%-68%) and 73% (95% CI, 68%-78%), respectively, for patients in CR (with a plateau in the curve beyond 15.9 years), 25% (95% CI, 19%-28%) and 49% (95% CI 42%-56%), respectively, for patients in PR, and 23% (95% CI, 8%-48%) and 28% (95% CI, 9%-45%), respectively, for patients with resistant/refractory disease (P 
YR 2017
FD 2017-05-19
LK https://hdl.handle.net/10668/25026
UL https://hdl.handle.net/10668/25026
LA en
DS RISalud
RD Apr 17, 2025